Chlamydia pneumoniae in coronary artery disease

Comment

E Gurfinkel et al. Circulation. 2000.

. 2000 Mar 14;101(10):E95.

doi: 10.1161/01.cir.101.10.e95.

No abstract available

Comment on

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.
Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Gupta S, et al. Circulation. 1997 Jul 15;96(2):404-7. doi: 10.1161/01.cir.96.2.404. Circulation. 1997. PMID: 9244203 Clinical Trial.
Antibiotic treatment trials for secondary prevention of coronary artery disease events.
Grayston JT. Grayston JT. Circulation. 1999 Mar 30;99(12):1538-9. doi: 10.1161/01.cir.99.12.1538. Circulation. 1999. PMID: 10096927 No abstract available.
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.
Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Anderson JL, et al. Circulation. 1999 Mar 30;99(12):1540-7. doi: 10.1161/01.cir.99.12.1540. Circulation. 1999. PMID: 10096928 Clinical Trial.